STX 241
Alternative Names: PFL-241; PFL-241/STX-241; STX-241Latest Information Update: 29 Aug 2024
At a glance
- Originator Pierre Fabre; Scorpion Therapeutics
- Developer Scorpion Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 22 Aug 2024 Pierre Fabre plans a phase I/II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, China, France, Germany, Netherlands, Spain (PO) (NCT06567015) (EudraCT2023-510203-21-00)
- 13 Oct 2023 Pharmacodynamics data from a preclinical studies in Non-small cell lung cancer released by Scorpion Therapeutics
- 11 Oct 2023 Pharmacodynamics data from a preclinical studies in Non-small cell lung cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)